Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
|Videos|July 22, 2021
Evolving Rehabilitation Strategies for Multiple Sclerosis
Ahmed Obeidat, MD, PhD; Francois Bethoux, MD; and Nicholas C. Ketchum, MD, discuss recent advancements and future directions in rehabilitation strategies for multiple sclerosis.
Advertisement
————————————
Panelists
- Ahmed Obeidat, MD, PhD
Assistant Professor, Department of Neurology, Neuroimmunology and Multiple Sclerosis; Director, Neuroimmunology and MS Fellowship Program, The Medical College of Wisconsin - Nicholas C. Ketchum, MD
Residency Program Director, Department of Physical Medicine and Rehabilitation, Medical College of Wisconsin - Francois Bethoux, MD
Director, Rehabilitation Services, Mellen Center for MS Treatment and Research, Cleveland Clinic
Key Learning Objectives
- Gait and ambulation in multiple sclerosis
- Spasticity and its management in multiple sclerosis
- Technology and rehabilitation in multiple sclerosis
- Traditional versus nontraditional approaches of rehabilitation in multiple sclerosis
Advertisement
Related to this article
A recent MS cohort study suggests that higher EBV nuclear antigen 1 antibody levels are associated with a lower risk of confirmed disability worsening, particularly among patients carrying both HLA-A02:01 and HLA-DRB115:01.
The FDA clearance allows AbelZeta to study bispecific CAR T-cell therapy C-CAR168 in refractory progressive multiple sclerosis.
Here's some of what is coming soon to NeurologyLive® this week.
A new case report underscored the need to consider CNS lymphoproliferative disease when patients on chronic immunosuppression for neuromyelitis optica spectrum disorder develop unexplained neurologic decline.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 11, 2026.
The FDA granted priority review to satralizumab for MOGAD, positioning it to become the first approved treatment for the rare autoimmune disease.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Levacetylleucine for Ataxia-Telangiectasia
2
FDA Clears Phase 1b/2 Trial of CAR T-Cell Therapy C-CAR168 for Refractory Progressive Multiple Sclerosis
3
FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A
4
Episode 175: Advancing the Ways of Treating Cluster Headache
5